Current Report Filing (8-k)
November 07 2017 - 3:52PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest
event reported): November 7, 2017
NEKTAR THERAPEUTICS
(Exact Name of Registrant as Specified in
Charter)
Delaware
|
0-24006
|
94-3134940
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
455 Mission Bay Boulevard South
San Francisco, California 94158
(Address of Principal Executive Offices and
Zip Code)
Registrant’s telephone number, including
area code: (415) 482-5300
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
|
|
Item 2.02
|
Results of Operations and Financial Condition.
|
On November 7, 2017, Nektar
Therapeutics, a Delaware corporation (“Nektar”), issued a press release (the “Press Release”) announcing
its financial results for the quarter ended September 30, 2017. A copy of the Press Release is furnished herewith as
Exhibit 99.1.
On October 31, 2017, Nektar
announced that it would hold a Webcast conference call on November 7, 2017 to review its financial results for the quarter ended
September 30, 2017. This conference call is accessible through a link that is posted on the home page and Investors section of
the Nektar website: http://www.nektar.com.
The information in this
report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and
12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not
be incorporated by reference into any filing with the Securities and Exchange Commission made by Nektar Therapeutics, whether made
before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirement of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
By:
|
/s/
|
Mark A. Wilson
|
|
|
Mark A. Wilson
|
|
|
General Counsel and Secretary
|
|
|
Date:
|
|
November 7, 2017
|
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From Apr 2024 to May 2024
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From May 2023 to May 2024